Peptide library / Heart & blood / Romiplostim
Romiplostim
A peptide-antibody fusion that stimulates platelet production in immune thrombocytopenia.
Effects studied or claimed
What it is used or promoted for, and where each effect has actually been seen
- Immune thrombocytopeniaFDA approved
- Radiation-related bone marrow injuryFDA approved
How it is thought to work
Romiplostim has peptides that bind and activate the thrombopoietin receptor, prompting the bone marrow to make platelets.
What the evidence shows
Pivotal trials showed durable platelet responses in a large share of patients compared with placebo.
Safety and unknowns
Headache, joint pain and bone marrow changes with long-term use.
Regulatory status
FDA-approved as Nplate in 2008.
Regulatory status changes quickly. This entry was last reviewed on 27 October 2026. Confirm current status with the FDA before relying on it.
More in Heart & blood
Rusfertide
In clinical trialsAn investigational hepcidin mimetic injected under the skin for polycythemia vera.
Selepressin
In clinical trialsA selective vasopressin V1a agonist tested in septic shock.
Pegcetacoplan
FDA-approvedA pegylated cyclic peptide that blocks complement C3, approved for a rare blood disorder and for an eye disease.
General information, not medical advice. Do not buy or inject unregulated peptides.